- Home
- CBL vs RCUS Comparison
CBL vs RCUS Comparison
Compare CBL & RCUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CBL
- RCUS
- Stock Information
- Founded
- CBL 1978
- RCUS 2015
- Country
- CBL United States
- RCUS United States
- Employees
- CBL N/A
- RCUS N/A
- Industry
- CBL Real Estate Investment Trusts
- RCUS Biotechnology: Pharmaceutical Preparations
- Sector
- CBL Real Estate
- RCUS Health Care
- Exchange
- CBL Nasdaq
- RCUS Nasdaq
- Market Cap
- CBL 771.2M
- RCUS 906.4M
- IPO Year
- CBL 1993
- RCUS 2018
- Fundamental
- Price
- CBL $25.85
- RCUS $8.36
- Analyst Decision
- CBL
- RCUS Buy
- Analyst Count
- CBL 0
- RCUS 10
- Target Price
- CBL N/A
- RCUS $23.75
- AVG Volume (30 Days)
- CBL 155.9K
- RCUS 1.2M
- Earning Date
- CBL 08-08-2025
- RCUS 08-07-2025
- Dividend Yield
- CBL 6.19%
- RCUS N/A
- EPS Growth
- CBL 2069.88
- RCUS N/A
- EPS
- CBL 2.16
- RCUS N/A
- Revenue
- CBL $528,212,000.00
- RCUS $141,000,000.00
- Revenue This Year
- CBL N/A
- RCUS N/A
- Revenue Next Year
- CBL N/A
- RCUS $28.73
- P/E Ratio
- CBL $11.75
- RCUS N/A
- Revenue Growth
- CBL 0.03
- RCUS N/A
- 52 Week Low
- CBL $21.10
- RCUS $6.50
- 52 Week High
- CBL $33.54
- RCUS $18.98
- Technical
- Relative Strength Index (RSI)
- CBL 51.12
- RCUS 39.01
- Support Level
- CBL $25.11
- RCUS $7.91
- Resistance Level
- CBL $26.09
- RCUS $8.87
- Average True Range (ATR)
- CBL 0.54
- RCUS 0.48
- MACD
- CBL 0.00
- RCUS -0.14
- Stochastic Oscillator
- CBL 54.76
- RCUS 8.24
About CBL CBL & Associates Properties Inc.
CBL & Associates Properties Inc is a real estate investment trust. The company engages in the ownership, development, acquisition, leasing, management and operation of regional shopping malls, outlet centers, lifestyle centers, open-air centers and other properties. CBL's sales predominantly derive from leasing arrangements with retail tenants. The company also generates revenue from management and development fees, as well as sales of its real estate assets. CBL expands its portfolio of assets through activities such as redevelopment, renovation, and expansion.
About RCUS Arcus Biosciences Inc.
Arcus Biosciences Inc is a clinical-stage biopharmaceutical company. It develops immunotherapies for the treatment of cancer. The company focuses on an ATP-adenosine pathway, which is a key driver of immunosuppression in the tumor microenvironment to create and optimize differentiated small-molecule immuno-oncology product candidates. Its product pipeline includes Domvanalimab, Etrumadenant, AB598, Casdatifan among others. Arcus conducts clinical trials for different types of cancers such as Lung, Colorectal, Pancreatic, and others. The company operates through a single segment which is the business of developing and commercializing immunotherapies.